CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the ...

SHARP is the First and Only Prospective Clinical Study in Patients With Chronic Kidney Disease to Show That an LDL Cholesterol-Lowering Medicine Reduced Major Vascular and Atherosclerotic Events "This ...

London, UK - It appears that a 10-mg dose of simvastatin is going to be made available over the counter (OTC) in the UK sometime in the near future for the primary prevention of coronary heart disease ...

To study the safety and efficacy of the combination tablet, investigators randomized 1528 patients with primary hypercholesterolemia to the ezetimibe/simvastatin combination or to simvastatin alone.

WHITEHOUSE STATION, N.J. & KENILWORTH, N.J. -- Merck/Schering-Plough Pharmaceuticals announced today the primary endpoint and other results of the ENHANCE (Effect of Combination Ezetimibe and ...

STOCKHOLM—New results suggest that combination therapy with ezetimibe/simvastatin, when prescribed at the recommended starting and next higher doses, is more likely to improve lipids than atorvastatin ...

The study enrolled patients within 10 days of ACS hospitalization who had sufficient risk as defined in the protocol and who had an initial LDL-C of ≤125 mg/dL if lipid-lowering drug naïve or <100 ...

Objective: To evaluate the safety and effectiveness of a simvastatin-to-lovastatin therapeutic conversion program. Study Design: Observational database study of a therapeuticconversion in members of ...

The American Heart Association (AHA) has released a new scientific statement for managing clinically significant drug-drug interactions in patients who are prescribed statins and other agents used in ...